Literature DB >> 16897589

Efficacy of voriconazole in experimental Cryptococcus neoformans infection.

Nikolaos Mavrogiorgos1, Oscar Zaragoza, Arturo Casadevall, Joshua D Nosanchuk.   

Abstract

Voriconazole is a third generation triazole with improved activity against many fungal pathogens. We examined the efficacy of voriconazole in a murine infection model and evaluated the drug's effect on cellular characteristics and serum polysaccharide levels. The antifungal reduced serum polysaccharide and significantly prolonged the survival of lethally infected animals.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16897589     DOI： 10.1007/s11046-006-0039-4

Source DB:  PubMed          Journal:  Mycopathologia        ISSN： 0301-486X            Impact factor:   3.785


  18 in total

1.  The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

Authors:  Sara A Mirza; Maureen Phelan; David Rimland; Edward Graviss; Richard Hamill; Mary E Brandt; Tracie Gardner; Matthew Sattah; Gabriel Ponce de Leon; Wendy Baughman; Rana A Hajjeh
Journal:  Clin Infect Dis       Date:  2003-02-27       Impact factor: 9.079

Review 2.  Clinical pharmacokinetics of voriconazole.

Authors:  Dominique Levêque; Yasmine Nivoix; François Jehl; Raoul Herbrecht
Journal:  Int J Antimicrob Agents       Date:  2006-03-24       Impact factor: 5.283

3.  Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia.

Authors:  S Schwartz; D Milatovic; E Thiel
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

4.  In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors:  M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.

Authors:  D J Hoban; G G Zhanel; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection.

Authors:  M Feldmesser; Y Kress; P Novikoff; A Casadevall
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

7.  Voriconazole treatment for less-common, emerging, or refractory fungal infections.

Authors:  John R Perfect; Kieren A Marr; Thomas J Walsh; Richard N Greenberg; Bertrand DuPont; Juliàn de la Torre-Cisneros; Gudrun Just-Nübling; Haran T Schlamm; Irja Lutsar; Ana Espinel-Ingroff; Elizabeth Johnson
Journal:  Clin Infect Dis       Date:  2003-04-22       Impact factor: 9.079

8.  Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure.

Authors:  S Sabbatani; R Manfredi; M Pavoni; A Consales; F Chiodo
Journal:  Mycopathologia       Date:  2004-08       Impact factor: 2.574

9.  Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates.

Authors:  S P Franzot; I F Salkin; A Casadevall
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 10.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441
View more
  4 in total

1.  Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).

Authors:  Eriques Gonçalves Silva; Claudete Rodrigues Paula; Francisco de Assis Baroni; Walderez Gambale
Journal:  Mycopathologia       Date:  2011-11-10       Impact factor: 2.574

2.  Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.

Authors:  Eriques Gonçalves Silva; Claudete Rodrigues Paula; Amanda Latercia Tranches Dias; Marilene Rodrigues Chang; Luciana da Silva Ruiz; Valderez Gambale; Renato Araujo Prates; Martha Simões Ribeiro
Journal:  Mycopathologia       Date:  2010-10-24       Impact factor: 2.574

3.  Voriconazole inhibits melanization in Cryptococcus neoformans.

Authors:  Luis R Martinez; Patricia Ntiamoah; Attila Gácser; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

4.  Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.

Authors:  Ting Zhao; Xiaolei Xu; Yushan Wu; Wei Zhang; Qin Zeng; Yanqiu Lu; Tongtong Yang; Guoqiang Zhou; Jianhua Yu; Ke Lan; Vijay Harypursat; Yaokai Chen
Journal:  BMC Infect Dis       Date:  2022-08-08       Impact factor: 3.667
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.